Study on correlation of biomarkers with squamous cell lung carcinoma
2018
University of Colorado Denver, Aurora, USA
Immunotherapy against marker PD-L1 has demonstrated success in the treatment of advanced non-small-cell lung cancer. However, few analyses exist on the adequacy of such treatment in early-stage squamous cell lung carcinoma (SqCLC). In this study, the researchers evaluated PD-L1 protein expression, tumor mutation burden, and expression of an immune gene signature in early-stage SqCLC patients. The researchers found that the studied biomarkers were independent of each other and none was associated with overall survival.
Correlation of PD-L1 expression with tumor mutation burden and gene signatures for prognosis in early-stage squamous cell lung carcinoma
Fred R. Hirsch
Added on: 07-27-2021
[1] https://www.jto.org/article/S1556-0864(18)33116-2/fulltext[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
